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We performed a case-control study to evaluate the
association between antibiotic use and Clostridium
difficile–associated diarrhea (CDAD), matching for admis-
sion unit and time at risk for CDAD. A multivariable regres-
sion model showed that treatment with fluoroquinolones
(odds ratio 12.7; 95% confidence interval 2.6 to 61.6) was
the strongest risk factor for CDAD. 
C
lostridium difficile–associated diarrhea (CDAD) is a
leading cause of nosocomial diarrhea in the United
States (1–4). On average, compared with patients without
this disease, patients in whom CDAD is diagnosed have
hospital stays that are 3.6 days longer and additional hos-
pital costs of $3,699 (5). Research has shown that patients
are usually exposed to C. difficile throughout their hospi-
talizations and that antibiotic use promotes the acquisition
of this organism (1). The outcome of acquisition, which
may be colonization or infection with C. difficile, is
thought to be determined primarily by patient factors
including advanced age and severity of underlying illness,
which may compromise the ability to mount an immune
response against the bacteria (6).
Clindamycin, penicillins, and cephalosporins have been
associated with CDAD (4). Although fluoroquinolones are
not currently believed to cause this illness, several case
reports of fluoroquinolone-associated C. difficile diarrhea
have been published (6–12). A case-control study of
patients at an acute-care hospital identified ciprofloxacin
use as a strong risk factor for nosocomial CDAD (13). The
broadened anti-anaerobic spectrum of newer fluoro-
quinolones raises the issue of whether therapy with these
agents can predispose this illness to develop in patients
(14).
Increasing rates of C. difficile infection in cases dis-
persed throughout our healthcare system prompted an
examination of patient-associated risk factors for CDAD.
We hypothesized that patients in whom CDAD was diag-
nosed were more likely to have received antibiotics of
which use had increased over the past year and that differ-
ences in antimicrobial drug–prescribing patterns could
account for the observed increase in cases.
The Study
The Veterans Affairs Maryland Health Care System
(VAMHCS) provides all medical services from intensive
care to ambulatory and pharmacy services for approxi-
mately 36,000 veterans at four separate inpatient sites. A
total of 778 beds are available for inpatient care, 120 of
which are dedicated to acute medical and surgical care.
Cases were defined as patients who were admitted to a
VAMHCS institution from January 1, 2001, to June 30,
2001, who had a new onset of diarrhea documented in their
medical records at least 72 hours after admission, a subse-
quent positive C. difficile toxin A enzyme immunoassay
result (Wampole Laboratories, Cranbury, NJ), and no
known history of CDAD. Patients with other reasons for
diarrhea, such as laxative use, were excluded. The date of
the positive C. difficile toxin test was considered to be the
date of CDAD diagnosis.
We selected two controls per case from patients admit-
ted to a VAMHCS institution for at least 48 hours during
the same 6-month period as the case-patients. Controls
were matched to the case-patients by unit of admission and
length of time at risk for development of CDAD (defined
below). We attempted to find two controls for each case
with a time at risk within 5 days of that of the case. When
finding such a control was not possible, we selected a con-
trol with the next closest length of time at risk. Controls
had no known history of CDAD and did not receive oral
metronidazole during their hospital stay in order to mini-
mize misclassification of controls that might be cases.
We collected data by reviewing electronic medical
records. Since antibiotic use up to 8 weeks before the
CDAD diagnosis has been implicated as causing infection
in previous studies (1,3), we examined both inpatient and
outpatient antibiotic use within the 6 weeks before diagno-
sis of CDAD for cases and for 6 weeks before hospital dis-
charge for controls. Specific use of clindamycin,
cephalosporins, fluoroquinolones, piperacillin-tazobac-
tam, and any other antibiotic drugs was recorded. The
number of days that fluoroquinolones were administered
to each patient was determined from medication orders and
nursing notes. Length of time at risk for CDAD was
defined as the number of days from admission to develop-
ment of the illness for cases and the number of days from
admission to discharge for controls. Demographic vari-
ables and details of hospital admission were also recorded,
including the unit where CDAD was diagnosed (cases) or
the admission unit (controls).
We compared characteristics of cases and controls with
the Wilcoxon rank-sum test for continuous variables and
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analysis of the association between individual variables
and case or control status was performed by using
Cochran-Mantel-Haenszel estimates. Conditional logistic
regression was used to assess the odds of CDAD develop-
ing in a patient. Variables significantly associated with
CDAD in our preliminary analysis were included in the
multivariable regression model. Confounding was
assessed by checking for a >10% change in the coefficient
estimate of covariates between models. A p value <0.05
was considered significant; all statistical tests were two-
tailed. Statistical analyses were performed by using SAS
software version 8.1 (SAS Institute, Inc., Cary, NC). 
Thirty patients met the case definition during the study
period; 60 controls were selected. The mean age of cases
and controls was not significantly different (Table 1). With
the exception of one female control, all patients were male.
Despite matching, case-patients had a longer length of
time at risk for CDAD, but the difference between cases
and controls was not statistically significant (p=0.18). Of
both cases and controls, 20% were admitted to general
medical units, 23% to general surgical units, 27% to suba-
cute or long-term care, 17 % to the medical intensive-care
unit, and 13% to the surgical intensive-care unit.
All 30 (100%) case-patients received antibiotics during
the 6 weeks before their CDAD diagnosis. In the compara-
ble 6-week window, 38 (63%) of the controls received
antibiotics (p<0.01 for difference). Both clindamycin and
fluoroquinolones were administered to a significantly
higher proportion of cases than controls. For the patients
who received fluoroquinolones, levofloxacin was pre-
scribed most often for both cases (60%) and controls
(60%), followed by ciprofloxacin (45% and 27%, respec-
tively), and gatifloxacin (14% and 20%, respectively).
These differences were not statistically significant. Among
the patients who received fluoroquinolones, 41% of case-
patients and 27% of controls received >1 week of fluoro-
quinolones (p=0.01). 
Matched univariate analysis of risk factors for CDAD
showed that fluoroquinolone use (odds ratio [OR] 13.5;
95% confidence interval [CI] 3.1 to 58.8) and clindamycin
use (OR 3.1; 95% CI 1.0 to 9.4) were associated with
developing this illness (Table 2). The results of the multi-
variable analysis are shown in Table 3. After confounding
from other antimicrobial agents was controlled for, fluoro-
quinolone use was significantly associated with an
increased risk of developing CDAD (OR 12.7; 95% CI 2.6
to 61.6).
Conclusions
Although ciprofloxacin-induced CDAD has been
reported, early reports were dismissed as being due to
other causes of diarrhea, including infection with
Salmonella and previous treatment with a different antibi-
otic (6–8,12). A group of bone marrow transplant patients
who received ciprofloxacin monotherapy for prophylaxis
against infection had no instances of CDAD, but two con-
current reports included cases of CDAD associated exclu-
sively with ciprofloxacin (9,10,15). Another report impli-
cated levofloxacin in eight of nine cases of CDAD in a
nursing home (11). Fluoroquinolone use was also identi-
fied as an independent predictor of a positive C. difficile
toxin assay in hospitalized patients (16). In addition, a
case-control study of patients at an acute-care hospital
identified ciprofloxacin use as a strong risk factor for noso-
comial CDAD with an OR >5 in each regression model
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Table 1. Characteristics of CDAD cases and matched controls, Veterans Affairs Maryland Health Care System, January 1, 2001–
June 30, 2001
a 
Characteristic  Cases (n=30)
b  Controls (n=60)
b  p value 
Age, median y   72 (66–79)
c  67 (56–76)
c  0.30 
Diagnosis causing admission        
Infectious   11 (37)  11 (18)  0.07 
Cardiovascular  5 (17)  14 (23)  0.59 
Neurologic/psychiatric  3 (10)  15 (25)  0.16 
Gastroenterologic  2 (7)  4 (7)  1.00 
Respiratory  1 (3)  5 (8)  0.66 
Other  8 (27)  11 (18)  0.42 
Antibiotics within 6 weeks   30 (100)  38 (63)  <0.01 
Cephalosporins   7 (23)  20 (33)  0.30 
Clindamycin   9 (30)  7 (12)  0.03 
Fluoroquinolones   22 (73)  15 (25)  <0.01 
Piperacillin/tazobactam   12 (40)  18 (30)  0.30 
All other antibiotics  17 (57)  27 (45)  0.30 
Days at risk for CDAD, median   21(10–30)
 c  13(7–25)
c  0.18 
aCDAD, Clostridium difficile–associated diarrhea. 
bUnless otherwise indicated, values in parentheses show percentages. 
cValue in parentheses shows interquartile range. (13). Thus, our study is consistent with more recent reports
that implicate fluoroquinolone use as a risk factor for
CDAD.
We found that the association between fluoro-
quinolones and CDAD is stronger than the association
between clindamycin and CDAD. However, the confi-
dence intervals are wide because of the small sample size
and overlap for the estimates, making a conclusion that
fluoroquinolones are a stronger risk factor for CDAD than
clindamycin inappropriate from our study. Because
patients commonly receive more than one antibiotic, accu-
rately measuring the effects of individual antibiotics in an
observational study is difficult. Concurrent prescribing of
clindamycin and fluoroquinolones may have biased the
estimates of the OR; however, only 32% of patients who
received fluoroquinolones also received clindamycin. In
the case-control study of acute-care patients by Yip et al.,
ciprofloxacin was also a stronger risk factor than clin-
damycin (13). 
Our study has a number of limitations. Since the study
was retrospective and we did not perform surveillance cul-
tures for C. difficile, we could not ascertain when this
organism was acquired; however, all cases received antibi-
otics before the diagnosis of CDAD. Thus, we conclude
that fluoroquinolones are clearly associated with C. diffi-
cile infection. On the basis of our study design, we could
not determine whether fluoroquinolones increase acquisi-
tion or promote infection once C. difficile is acquired.
Although we did not specifically assess the role of patient-
to-patient transmission in this study, we selected case-
patients and controls from the same hospital units and with
a similar risk period for developing the illness. Given the
strength of the association between fluoroquinolone use
and CDAD, more precise controlling for patient-to-patient
transmission is unlikely to eliminate the association.
If fluoroquinolone use is a stronger contributing factor
to C. difficile infection than other antibiotics, then restric-
tion of fluoroquinolone use among inpatients would result
in decreased CDAD rates. Climo et al. reported a decrease
in the incidence of CDAD at their institution after imple-
menting a formulary restriction of clindamycin (17).
However, the decision to restrict fluoroquinolone use
would need to be weighed against the clinical advantages
of using fluoroquinolones, such as convenient dosing and
excellent oral bioavailability (i.e., the ability of a drug to
achieve high serum levels when taken by mouth). We
observed a strong association between fluoroquinolone use
and CDAD in both our acute-care and long-term–care
patients, which supports a number of reports implicating
fluoroquinolones in the development of CDAD (6–11,13).
A prospective study of this association is warranted, given
the increasing use of fluoroquinolones and the excess com-
plications and costs associated with C. difficile infection
(5).
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